For example, sirolimus (rapamycin) has been demonstrated to be an effective agent in the treatment of lymphatic malformations by targeting the PIK3CA pathway, which is activated in the endothelial cells of these lesions54,55. The gene discussed is PIK3CA; the disease is lymphatic malformation.